LON:SAR Sareum (SAR) Share Price, News & Analysis GBX 16 -0.50 (-3.03%) As of 04:13 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Sareum Stock (LON:SAR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sareum alerts:Sign Up Key Stats Today's Range 16▼ 16.5050-Day Range 13.66▼ 20.6552-Week Range 11▼ 32Volume3,158 shsAverage Volume404,460 shsMarket Capitalization£19.99 millionP/E RatioN/ADividend Yield1.10%Price TargetN/AConsensus RatingN/A Company Overview Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage. Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802). Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients. SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance. Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company’s website at www.sareum.com Read More Receive SAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sareum and its competitors with MarketBeat's FREE daily newsletter. Email Address SAR Stock News HeadlinesSareum Holdings Expands Share Capital Through Warrant ExerciseApril 24, 2025 | msn.comNetflix war film leaves viewers in tears as they label it 'absolute masterpiece'April 23, 2025 | msn.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime. | Brownstone Research (Ad)Sareum served notice on commercial licence for cancer treatmentDecember 31, 2024 | lse.co.ukSareum Holdings Refocuses Strategy After SRA737 Licensing TerminationDecember 31, 2024 | markets.businessinsider.comSareum annual loss widens as remains focused on autoimmune diseasesOctober 29, 2024 | lse.co.ukLONDON MARKET CLOSE: Stocks end upbeat ahead of UK budgetOctober 29, 2024 | lse.co.ukGiving room for cottage industry products to shineOctober 18, 2024 | msn.comSee More Headlines SAR Stock Analysis - Frequently Asked Questions How have SAR shares performed this year? Sareum's stock was trading at GBX 24.60 at the beginning of 2025. Since then, SAR shares have decreased by 35.0% and is now trading at GBX 16. How were Sareum's earnings last quarter? Sareum Holdings plc (LON:SAR) announced its earnings results on Tuesday, March, 25th. The company reported ($0.90) EPS for the quarter. How do I buy shares of Sareum? Shares of SAR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Sareum own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sareum investors own include ReNeuron Group (RENE), ValiRx (VAL), Sierra Oncology (SRRA), Egdon Resources (EDR), Collagen Solutions plc (COS.L) (COS), Gulf Keystone Petroleum (GKP) and Summit Therapeutics (SMMT). Company Calendar Last Earnings3/25/2025Today8/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryFinancial Services Current SymbolLON:SAR CIKN/A Webwww.sareum.co.uk Phone+44-1223-497700FaxN/AEmployees3,211Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (4.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£5.28 million Net MarginsN/A Pretax MarginN/A Return on Equity-270.25% Return on Assets-113.80% Debt Debt-to-Equity RatioN/A Current Ratio4.22 Quick Ratio10.37 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 1.45 per share Price / Cash Flow11.32 Book ValueGBX 2.61 per share Price / Book6.28Miscellaneous Outstanding Shares124,928,001Free FloatN/AMarket Cap£20.49 million OptionableNot Optionable Beta-1.08 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (LON:SAR) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sareum Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Sareum With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.